TMCI trades 28.4% above Wall Street's consensus target of $3.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes TMCI achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, Treace Medical Concepts, Inc. (TMCI) has a Wall Street consensus price target of $3.00, based on estimates from 9 covering analysts. With the stock currently trading at $4.19, this represents a potential downside of -28.4%. The company has a market capitalization of $272M.
Analyst price targets range from a low of $3.00 to a high of $3.00, representing a 0% spread in expectations. The median target of $3.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 2 analysts rating the stock as a Buy or Strong Buy,6 rating it Hold, and 1 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, TMCI trades at a trailing P/E of -4.5x. Analysts expect EPS to grow +6.0% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
ANGOAngioDynamics, Inc. | $505M | $12.15 | $16.50 | +35.8% | Hold | — | 11 |
NVCRNovoCure Limited | $1.6B | $14.28 | $33.00 | +131.1% | Buy | — | 15 |
ATECAlphatec Holdings, Inc. | $1.3B | $8.81 | $18.00 | +104.3% | Buy | 27.5x | 18 |
OSUROraSure Technologies, Inc. | $306M | $4.25 | $4.00 | -5.9% | Hold | — | 13 |
PRCTPROCEPT BioRobotics Corporation | $1.2B | $21.72 | $32.00 | +47.3% | Buy | — | 15 |
CNMDCONMED Corporation | $1.0B | $32.58 | $78.00 | +139.4% | Hold | 7.5x | 21 |
MMSIMerit Medical Systems, Inc. | $4.0B | $67.22 | $94.20 | +40.1% | Buy | 16.5x | 14 |
IRTCiRhythm Technologies, Inc. | $3.4B | $104.65 | $188.75 | +80.4% | Buy | — | 20 |
TMDXTransMedics Group, Inc. | $2.7B | $78.79 | $121.20 | +53.8% | Buy | 38.9x | 12 |
ZBHZimmer Biomet Holdings, Inc. | $17.2B | $87.97 | $96.33 | +9.5% | Hold | 10.4x | 42 |
Quick answers to the most common questions about buying TMCI stock.
TMCI's consensus price target is $3, -28.4% below the current price of $4.19. The 9 analysts tracking TMCI see downside risk at present valuations.
TMCI has a consensus rating of "Hold" based on 9 Wall Street analysts. The rating breakdown is mixed, with 6 Hold ratings making up the largest segment. The consensus 12-month price target of $3 implies -28.4% downside from current levels.
TMCI's current price is $4.19 with a consensus target of $3 (-28.4% implied move). Analyst estimates suggest the stock is overvalued at current levels.
The most bullish Wall Street analyst has a price target of $3 for TMCI, while the most conservative target is $3. The consensus of $3 represents the median expectation. These targets typically reflect 12-month expectations.
TMCI is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 6 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month TMCI stock forecast based on 9 Wall Street analysts shows a consensus price target of $3, with estimates ranging from $3 (bear case) to $3 (bull case). The median consensus rating is "Hold".
Analysts are cautious on TMCI, with 1 Sell ratings and a price target of $3 (-28.4% from current price). The "Hold" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
TMCI analyst price targets range from $3 to $3, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $3 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.